Theodore Tollivoro, MD
Gastroenterology · Clackamas, ORNPI 1811230147
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 32.0% of the total. Reporting peaked in 2024 at $843 and has fallen 67.1% since, to $277 in 2025.
Across 85 payments — averaging $25.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$701
- Johnson & Johnson$320
- Lilly USA, LLC$185
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$126
- Gilead$104
- Pfizer$100
- plus $656 from 18 others
What the payments were for
- Food & beverage$2,17399%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 26 | $701 |
| Johnson & Johnson(2 entities) | 14 | $320 |
| Lilly USA, LLC | 6 | $185 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $126 |
| Gilead | 1 | $104 |
| Pfizer | 1 | $100 |
| Regeneron Healthcare Solutions, Inc. | 3 | $79 |
| Shire North American Group Inc | 4 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Echosens North America, Inc. | 1 | $59 |
| Boston Scientific | 3 | $57 |
| Shionogi Inc | 2 | $45 |
| Ipsen Biopharmaceuticals, Inc | 1 | $34 |
| Sanofi | 2 | $32 |
| Sandoz | 2 | $32 |
| Fresenius Kabi USA, LLC | 1 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Ferring Pharmaceuticals Inc. | 1 | $23 |
| Intercept Pharmaceuticals, Inc. | 1 | $22 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Celltrion USA Inc. | 1 | $18 |
| Bristol Myers Squibb | 1 | $17 |
| Ardelyx, Inc. | 1 | $16 |
| Redhill Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,191 in reported general payments places this provider in the 80th percentile of 220 gastroenterology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine | 17 | $5,624 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 50 | $3,433 |
| Pantoprazole Sodium | 106 | $1,863 |
| Omeprazole | 69 | $746 |
| Famotidine | 19 | $371 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Clackamas
- Averill GuoClackamas$4K
- Amit SadanaClackamas$2K
- Caroline TadrosClackamas$1K
- Donald LumPortland$320K
- Rebecca MatroPortland$154K
- Ian HolmesPortland$102K
- Amy ZhuPortland$72K
- Gregory CotePortland$58K
- Emily JonicaPortland$49K
- Rebecca FauselPortland$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.